NAD⁺ Precursors and Healthy Aging: What Do Human Studies Actually Show?

1. NR and NMN consistently affect NAD⁺ biology in humans

This was the clearest finding.

Oral NR and NMN consistently demonstrated biochemical target engagement. Human trials commonly found increases in circulating or cellular NAD-related metabolites after supplementation.

This confirms that these compounds are biologically active in humans.

However, biochemical target engagement represents only the first step in the evidence chain.

An increase in NAD-related biomarkers does not by itself demonstrate slower aging, improved healthspan or longer life.

2. Clinical benefits in humans are much less consistent

When researchers looked beyond biomarkers, the evidence became considerably more mixed.

Across human trials, effects on physical function, metabolic outcomes, vascular measures and other healthspan-related outcomes were heterogeneous.

Many outcomes showed no significant difference between treatment and control groups. Positive findings occurred, but they were often limited to particular endpoints or specific populations.

The evidence therefore supports an important distinction:

Biological activity is consistently demonstrated. Broad clinical anti-aging efficacy is not.

3. Animal studies are substantially more encouraging

The review included 80 rodent intervention studies.

Across these models, NAD⁺ augmentation was frequently associated with improvements in metabolic, mitochondrial, inflammatory and functional outcomes.

These findings provide important biological support for investigating NAD⁺ pathways in aging.

However, effects differed between experimental models and endpoints.

Animal studies can identify promising mechanisms and interventions, but they cannot establish clinical effectiveness in humans.

This translational gap is particularly important because much of the enthusiasm surrounding NAD⁺ and longevity originated from preclinical research.

4. Short-term tolerability of oral NR and NMN was generally favorable

Across the human studies included in the review, oral NR and NMN were generally well tolerated over periods ranging from weeks to months.

However, these relatively short study durations do not establish long-term safety when these compounds are taken chronically as longevity interventions.

This distinction matters because an intervention intended to influence aging might potentially be used for years rather than weeks or months.

5. Evidence for intravenous NAD⁺ is remarkably limited

This was one of the most clinically relevant findings of the review.

Despite the availability of intravenous NAD⁺ infusions in some wellness and longevity settings, the authors found no eligible clinical outcomes studies evaluating intravenous or intramuscular NAD⁺ itself for anti-aging or wellness purposes.

One nonrandomized study of intravenous NMN met the inclusion criteria. It provided mainly short-term safety and biomarker information.

A small pharmacokinetic study of intravenous NAD⁺ was also identified as contextual evidence, but it did not provide eligible clinical anti-aging outcomes.

The evidence supporting intravenous NAD⁺ as an anti-aging or healthspan intervention is therefore currently very limited.

6. The quality of the human evidence requires caution

The authors also assessed risk of bias.

Among the 28 randomized human trials:

1 was rated at overall low risk of bias

23 had some concerns

4 were rated at high risk of bias

All five nonrandomized human studies were rated as having a serious overall risk of bias.

The studies also differed considerably in participant populations, interventions, doses, duration and measured outcomes.

Because of this heterogeneity, the authors used a structured systematic synthesis rather than quantitatively pooling the results in a meta-analysis.

7. We still do not know whether NAD⁺ supplementation slows human aging

This is the central clinical conclusion.

NR and NMN can alter NAD-related biomarkers in humans. Some individual studies have also reported potentially beneficial functional, metabolic or physiological effects.

But current human evidence does not establish that NAD⁺ augmentation produces clinically meaningful anti-aging or healthspan benefits.

It has not been demonstrated that supplementation with NR or NMN slows biological aging, delays multiple age-related diseases or extends healthy lifespan in humans.

Larger, well-designed randomized trials with longer follow-up and predefined clinically meaningful outcomes are still needed.

NAD⁺ has become one of the most prominent targets in modern longevity science.

The current evidence supports continued investigation rather than either uncritical enthusiasm or outright dismissal.

For NR and NMN, we can say with reasonable confidence that they influence NAD⁺ biology in humans. We cannot yet say that this translates into slower aging or longer healthspan.

Some positive functional findings deserve further investigation and will be examined separately in the next Research Summary.

For intravenous NAD⁺, the evidence gap is substantially larger.

Ultimately, longevity medicine should ask not simply whether an intervention changes a molecular marker, but whether it helps people maintain function, delay disease and live more years in good health.

NAD⁺ research illustrates an important principle in longevity medicine:

Mechanistic plausibility, biomarker change and clinical benefit are three different levels of evidence.

NR and NMN have passed an important first test. They can modify the biological pathway they are intended to target in humans.

The more difficult question is whether this biochemical effect produces meaningful improvements in health and function.

Current human studies provide some encouraging signals, but the findings remain heterogeneous and frequently endpoint-specific. Current evidence does not establish clinically meaningful anti-aging or healthspan benefits.

The distinction is even more important for intravenous NAD⁺. Its availability in commercial longevity and wellness settings has moved considerably faster than clinical outcomes research.

Future studies need to determine whether particular NAD⁺-targeting interventions, doses, treatment durations or patient populations can produce reproducible clinical benefits.